Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: A real-world data analysis

Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: A real-world data analysis

BACKGROUND: Pegfilgrastim is available as a prefilled syringe (PFS) and an on-body injector (OBI). Whether the administration method of pegfilgrastim affects the effectiveness and health care resources has not been evaluated in the setting of routine care. OBJECTIVE: To compare real-world clinical a...

Full description

Bibliographic Details
Main Authors: Campbell, D. (Author), Campbell, K. (Author), Li, E. (Author), McBride, A. (Author), Schroader, B. (Author), Wang, W. (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
adult
Adult
aged
Aged
Aged, 80 and over
antineoplastic agent
Article
breast cancer
cancer chemotherapy
clinical outcome
clinical pharmacy
cohort analysis
controlled study
cyclophosphamide
data analysis
Data Analysis
devices
doxorubicin
drug cost
economic evaluation
economics
emergency ward
febrile neutropenia
female
Female
filgrastim
Filgrastim
health care cost
health care utilization
hospitalization
hospitalization cost
human
Humans
injection
Injections
macrogol
major clinical study
male
Male
middle aged
Middle Aged
multiple cycle treatment
nonhodgkin lymphoma
observational study
Outcome Assessment, Health Care
pegfilgrastim
Polyethylene Glycols
prophylaxis
Retrospective Studies
retrospective study
risk factor
rituximab
syringe
Syringes
very elderly
vincristine
young adult
Young Adult
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items